Document is current
Any future updates will be listed below
-
Authors
Flegar, Luka
Eisenmenger, Nicole
Reimold, Philipp
Koch, Rainer
Huber, Johannes
Groeben, Christer
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 2 December 2025
Accepted: 15 May 2026
First Online: 1 June 2026
Disclosure
: Dr. Luka Flegar has received fees from Novartis, AstraZeneca, and Astellas outside the presented work. Mrs. Nicole Eisenmenger is founder and director of RI Innovation GmbH. Dr. Huber has received grants and non-financial support from Intuitive Surgical, Takeda, Janssen, Apogepha, and Coloplast outside the submitted work and is a member of the medical board of the Urological Foundation for Health. Dr. Groeben has received fees from Janssen and Merck and Bayer outside the presented work. All other authors declare that they have no conflicts of interest.
: This study was conducted in accordance with the Declaration of Helsinki in its latest version. For data protection reasons, within the quality reports, the diagnostic (ICD) data or intervention numbers (OPS) with a number of ≤3 does not indicate the actual number, but the number 1. All data used are anonymized, so no further ethics committee approval was required. This article does not contain any studies with animals performed by any of the authors. Further, no written informed consent was required.
